Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France
| Autor: | Bruno Poulet, Alexander Valent, Jean-Pierre Ghnassia, Gaëtan MacGrogan, Lounes Djerroudi, Véronique Becette, Aurélie Maran-Gonzalez, Emmanuelle Charafe-Jauffret, Olivia Abramovici, Marie-Mélanie Dauplat, Cécile Blanc-Fournier, Yves Marie Robin, Agnès Leroux, Isabelle Treilleux, Frédérique Penault-Llorca, Elisabeth Russ, Paul Delrée, Eva Brabencova, Magali Lacroix-Triki, Pascal Roger, Juliette Haudebourg, Martine Antoine, Anca Berghian, Véronique Verriele, Patrick Michenet, Raphaëlle Duprez-Paumier, Marie-Pierre Chenard, Clémence Fleury, Anne Vincent-Salomon, Camille Franchet, Laurent Arnould, Lucie Tixier, Pour le Gefpics, Marie-Christine Mathieu |
|---|---|
| Přispěvatelé: | Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER |
| Jazyk: | francouzština |
| Rok vydání: | 2021 |
| Předmět: |
Clinical Oncology
0303 health sciences medicine.medical_specialty business.industry [SDV]Life Sciences [q-bio] medicine.disease 3. Good health Pathology and Forensic Medicine Clinical trial 03 medical and health sciences Status assessment 0302 clinical medicine Breast cancer 030220 oncology & carcinogenesis Family medicine Medicine Personalized medicine skin and connective tissue diseases business ComputingMilieux_MISCELLANEOUS 030304 developmental biology |
| Zdroj: | Annales de Pathologie Annales de Pathologie, Elsevier Masson, 2021, ⟨10.1016/j.annpat.2021.07.014⟩ |
| ISSN: | 0242-6498 |
| Popis: | The last international guidelines on HER2 determination in breast cancer have been updated in 2018 by the American Society of Clinical Oncology and College of American Pathologists, on the basis of a twenty-year practice and results of numerous clinical trials. Moreover, the emerging HER2-low concept for 1+ and 2+ non amplified breast cancers lead to refine French practices for HER2 status assessment. The GEFPICS group, composed of expert pathologists, herein presents the latest French recommendations for HER2 status evaluation in breast cancer, taking into account the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, HER2 status assessment remains one of the most important biomarkers in breast cancer and its quality guaranties the optimal patients' care. French pathologists' commitment in theranostic biomarker quality is more than ever required to provide the most efficient cares in oncology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|